AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

JAK Inhibitors for Psoriasis

Description

The presentation discusses the role of JAK inhibitors in the treatment of psoriasis, focusing on their mechanism of action and the latest updates on ducravacitinib, the only currently approved JAK inhibitor for this condition. It highlights the pathogenesis of psoriasis, emphasizing the significance of Type 1 interferons and the interleukin-23 signaling pathway in disease progression. Competitive and allosteric inhibitors are differentiated, with the latter gaining attention for their unique mechanism allowing other JAKs to function without interference. Ducravacitinib has shown promising results in clinical trials with significant percentages of patients achieving PASI 75 and PASI 90, along with a favorable safety profile and stability in laboratory parameters over time. Comparatively, other JAK inhibitors in development also display efficacy but may pose safety concerns typical of competitive inhibitors. The expert concludes that ducravacitinib represents a valuable treatment option within the arsenal for managing psoriasis, offering effective relief with minimal laboratory monitoring and risks, potentially suitable for patients dealing with multiple conditions.

View more

Conclusions

  • TYK2 plays a major role in psoriasis pathophysiology as a transducer of key cytokines such as Type 1 IFN, IL-12, and IL-23.
  • Deucravacitinib is the first allosteric JAK/TYK2 inhibitor approved for psoriasis, showing effectiveness with half of patients achieving PASI 90.
  • Patients maintained PASI 90 for up to 3 years while on Ducravacitinib.
  • Ducravacitinib has a good safety profile with no significant changes in laboratory parameters.
  • Allosteric inhibitors like Ducravacitinib demonstrate improved safety compared to competitive inhibitors due to greater selectivity.
  • Borzilleri RM et al. Burger's Medicinal Chemistry, Drug Discovery and Development; 8th ed. John Wiley & Sons; 2021.
  • Armstrong AW et al. J Am Acad Dermatol. 2022. doi:10.1016/j.jaad.2022.07.002.
  • Strober B et al. J Am Acad Dermatol. 2022. doi:10.1016/j.jaad.2022.08.061.
  • Tehlirian C et al. J Am Acad Dermatol. 2022. doi:10.1016/j.jaad.2022.03.059.
  • Forman SB et al. J Invest Dermatol. 2020;140:2359-2370.e5.
  • Nussinov R, Tsai C-J. Cell. 2013;153:293-305.
  • Imai K, Takaoka A. Nat Rev Cancer. 2006;6:714-727.
  • Krueger JG et al. J Amer Acad Dermatol. 2022;86:148-157.
  • Tokarski JS et al. J Biol Chem. 2015;290:11061-11074.
  • Berg JM et al. Biochemistry. 5th ed. 2002.
  • Müller S, Chaikuad A, Gray NS, Knapp S. Nat Chem Biol. 2015;11:818-821.
  • Attwood MM et al. Nat Rev Drug Discov. 2021;20:839-861.
  • Mcinnes, I.B . et al ., 2021. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. New England Journal of Medicine 384, 1227-1239 .. https://dol.org/10.1056/nejmoa2022516
  • Mease, P.J ., et al ., 2021. Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study. Rheumatology and Therapy 8, 903-919 .. https://doi.org/10.1007/s40744-021-00305-z